The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: A positron emission tomography study with [ 11C]-(+)-PHNO

Archives of General Psychiatry

Volumn 66, Issue 6, 2009, Pages 606-615

  Graff Guerrero, Ariel ^a,b   Mamo, David ^a   Shammi, C M ^a   Mizrahi, Romina ^a   Marcon, Heidi ^a   Barsoum, Penny ^a   Rusjan, Pablo ^a   Houle, Sylvain ^a   Wilson, Alan A ^a   Kapur, Shitij ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE C 11; OLANZAPINE; PRAMIPEXOLE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN SCINTIANGIOGRAPHY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLOBUS PALLIDUS; HUMAN; LIGAND BINDING; MALE; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; PUTAMEN; RADIOISOTOPE DISTRIBUTION; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BENZODIAZEPINES; BENZOTHIAZOLES; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CAUDATE NUCLEUS; CLOZAPINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; GLOBUS PALLIDUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISPERIDONE; SCHIZOPHRENIA;

EID: 66449106317     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.43     Document Type: Article

References (68)

1. Delay J, Deniker P, Harl J-M. Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP) [in French]. Ann Med Psychol (Paris). 1952;110(2:1):112-117.
2. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188(4194):1217-1219.
3. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45(1):71-76. (Pubitemid 18018572)
4. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995;57(10):PL103-PL107.
5. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. (Pubitemid 30191189)
6. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553-559. (Pubitemid 30349435)
7. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161(5):818-825. (Pubitemid 38625334)
8. Nordström AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res. 1995;61(2):67-83.
9. Nordström AL, Nyberg S, Olsson H, Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry. 1998;55(3):283-284.
10. Frankle WG, Laruelle M. Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med. 2002;16(7):437-446. (Pubitemid 36013940)
11. Talbot PS, Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol. 2002;12(6):503-511. (Pubitemid 35408701)
12. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med. 1993;23(3):791-797. (Pubitemid 23268097)
13. Scaramellini C, Leff P. A three-state receptor model: predictions of multiple agonist pharmacology for the same receptor type. Ann N Y Acad Sci. 1998;861:97-103. (Pubitemid 29047705)
14. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci. 1995;16(3):89-97.
15. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'dowd BF, George SR, Perreault ML, Männistö PT, Robinson S, Palmiter RD, Tallerico T. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A. 2005;102(9):3513-3518.
16. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979- 2986. (Pubitemid 46438984)
17. Sokoloff P, Andrieux M, Besancon R, Pilon C, Martres MP, Giros B, Schwartz JC. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol. 1992;225(4):331-337.
18. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994;268(1):417-426.
19. Seeman P, Ko F, Willeit M, McCormick P, Ginovart N. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse. 2005;58(2):122-128. (Pubitemid 41443748)
20. Vanhauwe JF, Josson K, Luyten WH, Driessen AJ, Leysen JE. G-protein sensitivity of ligand binding to human dopamine D(2) and D(3) receptors expressed in Escherichia coli: clues for a constrained D(3) receptor structure. J Pharmacol Exp Ther. 2000;295(1):274-283.
21. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry. 2006;59(5):389-394. (Pubitemid 43289216)
22. Seeman P, Ulpian C, Larsen RD, Anderson PS. Dopamine receptors labelled by PHNO. Synapse. 1993;14(4):254-262. (Pubitemid 23231004)
23. Parker C, Clarke K, Gee AD, Gee A, Rabiner E. In vitro characterisation of the high affinity D2/D3 dopamine agonist (+)PhNO. Neuroimage. 2006;31(suppl 2):T29.
24. Nobrega JN, Seeman P. Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO. Synapse. 1994;17(3):167-172. (Pubitemid 24204342)
25. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S. Brain region binding of the D(2/3) agonist [(11) C]-(+)-PHNO and the D(2/3) antagonist [(11)C]raclopride in healthy humans. Hum Brain Mapp. 2008;29(4):400-410.
26. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M. Dopamine (D(2/3)) receptor agonist positron emission tomography radiotracer [(11)C]-(+)-PHNO is a D(3) receptor preferring agonist in vivo. Synapse. 2006;60(7):485-495.
27. Abi-Saab W, Graff Guerrero A, Redden L, et al. First demonstration of D3 occupancy in humans: blockade of [11C]-(+)-PHNO PET by ABT-925. Paper presented at: Society of Biological Psychiatry; May 1-3, 2008; Washington, DC.
28. Rabiner E, Slifstein M, Gunn K, et al. D3 receptor quantification with [11C]-(+)- PHNO PET. Paper presented at: ACNP 46th Annual Meeting; 2007; Boca Raton, FL.
29. Rabiner E, Raymond R, Diwan M, McCormick P, Wilson A, Nobrega J. D3 and D2 components of ex vivo regional (+)-PHNO brain binding in wild-type and knockout mice. In: Society of Nuclear Medicine Annual Meeting Abstracts. Vol 48. Reston, VA: Society of Nuclear Medicine; 2007:113P-b.
30. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab. 2007;27(4):857-871. (Pubitemid 46474628)
31. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. (Pubitemid 29001829)
32. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4, 4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9 -ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem. 2005;48(12):4153-4160. (Pubitemid 40800622)
33. Wilson AA, Garcia A, Jin L, Houle S. Radiotracer synthesis from [11C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol. 2000;27(6):529-532.
34. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, Tetsuya S, Houle S, Kapur S. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006;147(1):79-89. (Pubitemid 44067435)
35. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S. First human evidence of d-amphetamine induced displacement of a D(2/3) agonist radioligand: a [(11)C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology. 2008;33(2):279-289. (Pubitemid 350243342)
36. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3, pt 1):153-158. (Pubitemid 27024284)
37. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539. (Pubitemid 47301451)
38. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16(1):42-52. (Pubitemid 126442313)
39. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab. 1998;18(9):941-950. (Pubitemid 28427861)
40. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23(9):1096-1112. (Pubitemid 37082435)
41. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6(4):279-287. (Pubitemid 28018717)
42. Friston KJ. Commentary and opinion, II: statistical parametric mapping. Ontology and current issues. J Cereb Blood Flow Metab. 1995;15(3):361-370.
43. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S. The dopamineD2receptors in high-affinity state andD3receptorsinschizophrenia: aclinical[11C]-(+)-PHNOPETstudy. Neuropsychopharmacology. 2009;34(4):1078-1086.
44. Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N- di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A. 1992;89(17):8155-8159.
45. Erdely HA, Tamminga CA, Roberts RC, Vogel MW. Regional alterations in RGS4 protein in schizophrenia. Synapse. 2006;59(8):472-479.
46. Salahpour A, Angers S, Bouvier M. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol Metab. 2000;11(5):163-168. (Pubitemid 30457135)
47. Elmhurst JL, Xie Z, O'Dowd BF, George SR. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Brain Res Mol Brain Res. 2000;80(1):63-74. (Pubitemid 30612438)
48. Wang W, Hahn KH, Bishop JF, Gao DQ, Jose PA, Mouradian MM. Up-regulation of D3 dopamine receptor mRNA by neuroleptics. Synapse. 1996;23(3):232-235. (Pubitemid 26235233)
49. D'Souza U, McGuffin P, Buckland PR. Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA. Neuropharmacology. 1997;36(11-12):1689-1696.
50. Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Psychopharmacology (Berl). 1996;128(4):362-370. (Pubitemid 26417678)
51. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001;297 (2):711-717. (Pubitemid 32378004)
52. Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997;280(2):561-569. (Pubitemid 27171313)
53. Joyce JN. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse. 2001;40(2):137-144. (Pubitemid 32239595)
54. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia: a postmortem study. Arch Gen Psychiatry. 1997;54(3):225-232. (Pubitemid 27132051)
55. Lévesque D, Martres MP, Diaz J, Griffon N, Lammers CH, Sokoloff P, Schwartz JC. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A. 1995;92(5):1719-1723.
56. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem. 2006;97(4):1089-1103.
57. McCormick PN, Kapur S, Seeman P, Wilson AA. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol. 2008;35(1):11-17. (Pubitemid 350298245)
58. Roberts DJ, Strange PG. Mechanisms of inverse agonist action at D2 dopamine receptors. Br J Pharmacol. 2005;145(1):34-42. (Pubitemid 40675546)
59. Murray AM, Ryoo H, Joyce JN. Visualization of dopamine D3-like receptors in human brain with [125I]epidepride. Eur J Pharmacol. 1992;227(4):443-445.
60. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999;20(1):60-80. (Pubitemid 29010341)
61. Rabiner E, Slifstein M, Gunn R, et al. First quantification of D3 receptors in vivo: PET with [11C]PHNO and [11C]fallypride. Paper presented at: Society of Biological Psychiatry Annual Meeting; 2008; Washington, DC.
62. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164(9):1411-1417. (Pubitemid 47461142)
63. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, Costello MR, Farahi J, Saxena S, Monterosso J, London ED. Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology. 2009;34(2):282-289.
64. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [(11)C]raclopride. Synapse. 2004;54(2):65-71. (Pubitemid 39315091)
65. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM. The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse. 2007;61(8):637-645. (Pubitemid 46934011)
66. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-157. (Pubitemid 40812332)
67. Camacho-Ochoa M, Walker EL, Evans DL, Piercey MF. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. Neurosci Lett. 1995;196(1-2):97-100.
68. Piercey MF, Walker EL, Feldpausch DL, Camacho-Ochoa M. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Lett. 1996;219(2):138-140. (Pubitemid 26396334)